Advertisement Pharmaceutical Business review - Page 4248 of 5286 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
August 19, 2026

Andelyn Biosciences to develop GM2 gangliosidosis therapy

Andelyn Biosciences is set to develop and manufacture a gene therapy known as AAV9-GM2, for Queen’s University to treat GM2 gangliosidoses, including Tay-Sachs and Sandhoff diseases.

Using its platform, Andelyn Biosciences plans to implement a multi-phase programme. Credit: Gorodenkoff / Shutterstock.com.